Founded with the mission to address unmet medical needs in cardiovascular disease, XyloCor Therapeutics is a biotechnology company specializing in the development of first-in-class gene therapies. Their primary focus is on creating innovative treatments for advanced coronary artery disease. The company's lead candidate, XC001, is currently undergoing clinical trials aimed at improving the quality of life for patients suffering from severe cardiovascular conditions.
XyloCor Therapeutics has garnered attention for its promising EXACT Phase 2 data for XC001, presented at the Society for Cardiovascular Angiography & Interventions (SCAI) 2024. The company's advancements in gene therapy have positioned it as a significant player in the biotech industry, with a dedicated team of scientists and support from notable investors. Their work has the potential to revolutionize treatment paradigms in cardiovascular medicine, offering hope to patients with limited options.
